Jim Cramer Expects Palantir To Reach New All-Time High

Group 1 - Investor sentiment is influenced by clinical trial results, technological advancements, and corporate partnerships, making market analysis essential for navigating investment opportunities [1] - Viking Therapeutics, Inc. (VKTX) has shown a downward bias following the release of Phase 2 trial data for its VK2735 pill, a dual agonist targeting GLP-1 and GIP receptors [2] - Palantir Technologies Inc. (PLTR) shares are expected to reach $200 according to market commentary [2] Group 2 - Richtech Robotics Inc. (RRR) announced a $100 million at-the-market offering, indicating a significant capital raise [3] - Richtech Robotics shares declined by 5.2% to close at $2.5400, reflecting market sentiment [5] - Viking Therapeutics shares fell by 1.2% to settle at $26.53, indicating a negative market reaction [5]